The product is administered rectally. Each suppository contains as an active ingredient human recombinant interferon alpha-2b in the specified dosages (150,000 IU, 500,000 IU, 1,000,000 IU, 3,000,000 IU).
Acute respiratory viral infections, including influenza, including those complicated by bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of comprehensive therapy.
The recommended dose for adults, including pregnant women and children over 7 years of age, is VIFERON® 500,000 IU per 1 suppository twice a day every 12 hours daily for 5 days. Therapy may be continued based on clinical indications.
For children up to 7 years old, including newborns and premature babies with a gestational age of more than 34 weeks, it is recommended to use VIFERON® 150,000 IU per 1 suppository twice a day every 12 hours daily for 5 days. Therapy may be continued based on clinical indications. The interval between courses is 5 days.
For premature newborns with a gestational age of less than 34 weeks, it is recommended to use VIFERON® 150,000 IU per 1 suppository three times a day every 8 hours daily for 5 days. Therapy may be continued based on clinical indications. The interval between courses is 5 days.
Infectious-inflammatory diseases of newborns, including premature babies: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of comprehensive therapy.
The recommended dose for newborns, including premature babies with a gestational age of more than 34 weeks, is VIFERON® 150,000 IU once daily per 1 suppository twice a day every 12 hours. The course of treatment is 5 days.
For premature newborns with a gestational age of less than 34 weeks, it is recommended to use VIFERON® 150,000 IU once daily per 1 suppository three times a day every 8 hours. The course of treatment is 5 days.
The recommended number of courses for various infectious-inflammatory diseases: sepsis – 2-3 courses, meningitis – 1-2 courses, herpes infection – 2 courses, enterovirus infection – 1-2 courses, cytomegalovirus infection – 2-3 courses, mycoplasmosis, candidiasis, including visceral – 2-3 courses. The interval between courses is 5 days. Therapy may be continued based on clinical indications.
Chronic viral hepatitis B, C, D in children and adults as part of comprehensive therapy, including in combination with plasmapheresis and hemosorption for chronic viral hepatitis with severe activity, complicated by liver cirrhosis.
The recommended dose for adults is VIFERON® 3,000,000 IU per 1 suppository twice a day every 12 hours daily for 10 days, then three times a week every other day for 6-12 months. The duration of treatment is determined by clinical effectiveness and laboratory parameters.
For children under 6 months of age, a dose of 300,000-500,000 IU per day is recommended; for children aged 6 to 12 months – 500,000 IU per day.
For children aged 1 year to 7 years, a dose of 3,000,000 IU per 1 m2 of body surface area per day is recommended.
For children over 7 years of age, a dose of 5,000,000 IU per 1 m2 of body surface area per day is recommended.
The drug is administered twice a day every 12 hours for the first 10 days daily, then three times a week every other day for 6-12 months. The duration of treatment is determined by clinical effectiveness and laboratory parameters.
The daily dose of the drug for each patient is calculated by multiplying the recommended dose for the age by the body surface area calculated using the Garford, Terry, and Rurk nomogram for calculating body surface area based on height and weight. The single dose is calculated by dividing the calculated daily dose by 2 administrations, and the resulting value is rounded up to the suppository dosage.
For chronic viral hepatitis with severe activity and liver cirrhosis before plasmapheresis and/or hemosorption, it is recommended to use VIFERON® 150,000 IU for children under 7 years of age, and VIFERON® 500,000 IU for children over 7 years of age, 1 suppository twice a day every 12 hours daily for 14 days.
Infectious-inflammatory diseases of the urogenital tract (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) in adults, including pregnant women, as part of comprehensive therapy.
The recommended dose for adults is VIFERON® 500,000 IU per 1 suppository twice a day every 12 hours daily for 5-10 days. Therapy may be continued based on clinical indications.
For pregnant women from the second trimester of pregnancy (starting from the 14th week of gestation), it is recommended to use VIFERON® 500,000 IU per 1 suppository twice a day every 12 hours daily for 10 days, then for 9 days, 3 times with an interval of 3 days (on the fourth day) per 1 suppository twice a day every 12 hours. Then every 4 weeks until delivery, VIFERON® 150,000 IU per 1 suppository twice a day every 12 hours daily for 5 days. If necessary, it is recommended to use the drug before delivery (from the 38th week of gestation) VIFERON® 500,000 IU per 1 suppository twice a day every 12 hours daily for 10 days.
Primary or recurrent herpetic infection of the skin and mucous membranes, localized form, mild to moderate course, including urogenital form in adults, including pregnant women.
The recommended dose for adults is VIFERON® 1,000,000 IU per 1 suppository twice a day every 12 hours daily for 10 days and more for recurrent infection. Therapy may be continued based on clinical indications. It is recommended to start treatment immediately at the first signs of skin and mucous membrane lesions (itching, burning, redness). For the treatment of recurrent herpes, it is desirable to start treatment in the prodromal period or at the onset of signs of recurrence.
For pregnant women from the second trimester of pregnancy (starting from the 14th week of gestation), it is recommended to use VIFERON® 500,000 IU per 1 suppository twice a day every 12 hours daily for 10 days, then for 9 days, 3 times with an interval of 3 days (on the fourth day) per 1 suppository twice a day every 12 hours. Then every 4 weeks until delivery, VIFERON® 150,000 IU per 1 suppository twice a day every 12 hours daily for 5 days. If necessary, it is recommended to use the drug before delivery (from the 38th week of gestation) VIFERON® 500,000 IU per 1 suppository twice a day every 12 hours daily for 10 days.
Viral meningitis in children aged 4 years and older as part of comprehensive therapy.
The recommended dose for children from 4 to 11 years old is VIFERON® 1,000,000 IU per 1 suppository twice a day every 12 hours daily for 7 days, then 1,000,000 IU per 1 suppository once a day (at night) daily
